blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3749671

EP3749671 - [1,2,4]TRIAZOLO[4,3-A]PYRAZIN-8-ONE DERIVATIVES [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  02.02.2024
Database last updated on 24.08.2024
FormerThe patent has been granted
Status updated on  24.02.2023
FormerGrant of patent is intended
Status updated on  19.10.2022
FormerExamination is in progress
Status updated on  15.10.2021
FormerRequest for examination was made
Status updated on  13.11.2020
FormerThe international publication has been made
Status updated on  17.08.2019
Formerunknown
Status updated on  11.03.2019
Most recent event   Tooltip17.05.2024Lapse of the patent in a contracting state
New state(s): SI		published on 19.06.2024  [2024/25]
Applicant(s)For all designated states
Eli Lilly and Company
Lilly Corporate Center
Indianapolis, IN 46285 / US
[2023/13]
Former [2020/51]For all designated states
Eli Lilly and Company
Lilly Corporate Center
Indianapolis, IN 46285 / US
Inventor(s)01 / CAMP, Nicholas Paul
c/o ELI LILLY AND COMPANY P.O. Box 6288
Indianapolis, Indiana 46206-6288 / US
02 / HAMDOUCHI, Chafiq
c/o ELI LILLY AND COMPANY P.O. Box 6288
Indianapolis, Indiana 46206-6288 / US
03 / LINESWALA, Jayana Pankaj
c/o ELI LILLY AND COMPANY P.O. Box 6288
Indianapolis, Indiana 46206-6288 / US
04 / MORPHY, John Richard
c/o ELI LILLY AND COMPANY P.O. Box 6288
Indianapolis, Indiana 46206-6288 / US
05 / SHI, Qing
c/o ELI LILLY AND COMPANY P.O. Box 6288
Indianapolis, Indiana 46206-6288 / US
 [2020/51]
Representative(s)J A Kemp LLP
80 Turnmill Street
London EC1M 5QU / GB
[2023/13]
Former [2020/51]Ingham, Stephen Howard
Eli Lilly and Company Limited
8 Arlington Square West Downshire Way
Bracknell, Berkshire RG12 1PU / GB
Application number, filing date19707923.930.01.2019
[2020/51]
WO2019US15757
Priority number, dateUS201862626745P06.02.2018         Original published format: US 201862626745 P
[2020/51]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2019156861
Date:15.08.2019
Language:EN
[2019/33]
Type: A1 Application with search report 
No.:EP3749671
Date:16.12.2020
Language:EN
The application published by WIPO in one of the EPO official languages on 15.08.2019 takes the place of the publication of the European patent application.
[2020/51]
Type: B1 Patent specification 
No.:EP3749671
Date:29.03.2023
Language:EN
[2023/13]
Search report(s)International search report - published on:EP15.08.2019
ClassificationIPC:C07D487/04, A61P13/12, A61K31/4985
[2020/51]
CPC:
C07D487/04 (EP,US); A61P13/12 (EP)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2020/51]
Extension statesBANot yet paid
MENot yet paid
Validation statesKHNot yet paid
MANot yet paid
MDNot yet paid
TNNot yet paid
TitleGerman:[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-8-ON-DERIVATE[2020/51]
English:[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-8-ONE DERIVATIVES[2020/51]
French:DÉRIVÉS DE [1,2,4]TRIAZOLO[4,3-A]PYRAZIN-8-ONE[2020/51]
Entry into regional phase07.09.2020National basic fee paid 
07.09.2020Designation fee(s) paid 
07.09.2020Examination fee paid 
Examination procedure04.09.2020Amendment by applicant (claims and/or description)
07.09.2020Examination requested  [2020/51]
07.09.2020Date on which the examining division has become responsible
19.10.2021Despatch of a communication from the examining division (Time limit: M06)
11.04.2022Reply to a communication from the examining division
19.10.2022Communication of intention to grant the patent
14.02.2023Fee for grant paid
14.02.2023Fee for publishing/printing paid
14.02.2023Receipt of the translation of the claim(s)
Opposition(s)03.01.2024No opposition filed within time limit [2024/10]
Fees paidRenewal fee
01.02.2021Renewal fee patent year 03
04.01.2022Renewal fee patent year 04
03.01.2023Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAT29.03.2023
CZ29.03.2023
DK29.03.2023
EE29.03.2023
FI29.03.2023
HR29.03.2023
LT29.03.2023
LV29.03.2023
PL29.03.2023
RO29.03.2023
RS29.03.2023
SE29.03.2023
SI29.03.2023
SK29.03.2023
SM29.03.2023
NO29.06.2023
IS29.07.2023
PT31.07.2023
[2024/25]
Former [2024/10]AT29.03.2023
CZ29.03.2023
DK29.03.2023
EE29.03.2023
FI29.03.2023
HR29.03.2023
LT29.03.2023
LV29.03.2023
PL29.03.2023
RO29.03.2023
RS29.03.2023
SE29.03.2023
SK29.03.2023
SM29.03.2023
NO29.06.2023
IS29.07.2023
PT31.07.2023
Former [2023/50]AT29.03.2023
EE29.03.2023
FI29.03.2023
HR29.03.2023
LT29.03.2023
LV29.03.2023
PL29.03.2023
RO29.03.2023
RS29.03.2023
SE29.03.2023
SK29.03.2023
SM29.03.2023
NO29.06.2023
IS29.07.2023
PT31.07.2023
Former [2023/49]AT29.03.2023
EE29.03.2023
FI29.03.2023
HR29.03.2023
LT29.03.2023
LV29.03.2023
RO29.03.2023
RS29.03.2023
SE29.03.2023
SM29.03.2023
NO29.06.2023
PT31.07.2023
Former [2023/48]AT29.03.2023
EE29.03.2023
FI29.03.2023
HR29.03.2023
LT29.03.2023
LV29.03.2023
RS29.03.2023
SE29.03.2023
SM29.03.2023
NO29.06.2023
PT31.07.2023
Former [2023/46]FI29.03.2023
HR29.03.2023
LT29.03.2023
LV29.03.2023
RS29.03.2023
SE29.03.2023
SM29.03.2023
NO29.06.2023
PT31.07.2023
Former [2023/36]FI29.03.2023
HR29.03.2023
LT29.03.2023
LV29.03.2023
RS29.03.2023
SE29.03.2023
NO29.06.2023
Former [2023/35]HR29.03.2023
LT29.03.2023
RS29.03.2023
NO29.06.2023
Former [2023/34]LT29.03.2023
RS29.03.2023
Former [2023/33]LT29.03.2023
Cited inInternational search[YD]WO2016055618  (LUNDBECK & CO AS H [DK]) [YD] 1-15 * Whole document, particularly claims 1 and examples 6, 7, 30 and 79-84; pages 1-3 *;
 [YD]WO2017139186  (LILLY CO ELI [US]) [YD] 1-15* Whole document, particularly clam 1, and Tables 1-3 *
by applicantWO2016055618
 US2017233396
    - GOULD, P.L., "Salt selection for basic drugs", International Journal of Pharmaceutics, (19860000), vol. 33, doi:doi:10.1016/0378-5173(86)90055-4, pages 201 - 217, XP025813036

DOI:   http://dx.doi.org/10.1016/0378-5173(86)90055-4
    - BASTIN, R.J. et al., "Salt Selection and Optimization Procedures for Pharmaceutical New Chemical Entities", Organic Process Research and Development, (20000000), vol. 4, pages 427 - 43 5
    - BERGE, S.M. et al., "Pharmaceutical Salts", Journal of Pharmaceutical Sciences, (19770000), vol. 66, doi:doi:10.1002/jps.2600660104, pages 1 - 19, XP002675560

DOI:   http://dx.doi.org/10.1002/jps.2600660104
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.